ICON's AI-directed video engine cuts clinical trial video production time by 90%, streamlining site selection and training ...

Citius Oncology presents LYMPHIR quality-of-life data from pivotal Study 302 at EORTC meeting, supporting formulary ...

Eton's ET-700 shows better tolerability than GALZIN but reduced efficacy in Wilson disease pilot study with 12 patients per ...

Ivonescimab perioperative NSCLC study shows 50.7% pathological complete response rate, outpacing current standard-of-care ...

BRII-179 showed 32% HBsAg loss durability at 24 weeks post-treatment in the Phase 2b ENRICH study, with consistent results ...

ATG-201 Phase I trial opens in China for B cell autoimmune diseases, testing a CD19×CD3 bispecific with masking technology to ...

Clinical research sites report trial complexity as their top operational problem, with 41% naming it their biggest challenge ...

Pentixapharm cleared a meaningful regulatory hurdle this week: the FDA raised no concerns about the protocol for the Phase 3 PANDA study, submitted in August 2026, leaving the design intact at ...

On November 2, 2026, Bright Minds Biosciences learned about a partial clinical hold on its IND for BMB-101 in Developmental and Epileptic Encephalopathies via email. Not a Type A meeting. Not a formal ...

78% of moderate aortic stenosis patients have high-risk features that double mortality and heart failure hospitalization risk within two years, study shows.

Eton Pharma's ET-900 program tests mecasermin injection for refractory infantile spasms, with first patient dosing planned for Q1 2027.

PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...